Stockscreener 앱 받기
7.88
1.68%
0.13
시간 외 거래:
8.00
0.12
+1.52%
Grifols Sa Adr 주식(GRFS)의 최신 뉴스
[Latest] Global Botulinum Toxin in Urology Market Size/Share Worth USD 1.98 Billion by 2035 at a 6.08% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.
Grifols doses first patients in two phase 3 immunoglobulin trials By Investing.com - Investing.com UK
ETFs Investing in Grifols, S.A. Sponsored ADR Class B Stocks - TradingView
G0FB Forecast — Price Target — Prediction for 2027 - TradingView
GRFSGrifols SA ADR Options - Finviz
G0F Forecast — Price Target — Prediction for 2027 - TradingView
Grifols operations profile, Sunday focus on plasma and strategy - ad-hoc-news.de
A1C3HH Forecast — Price Target — Prediction for 2027 - TradingView
Grifols, S.A. Class A Actuals & Estimates (BME:GRF) - TradingView
A1J1E2 Forecast — Price Target — Prediction for 2027 - TradingView
Grifols, S.A. Sponsored ADR Class B Actuals & Estimates (NASDAQ:GRFS) - TradingView
Grifols holds technical support, shares trade in a tight Nasdaq range - AD HOC NEWS
Grifols SA (GRFS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Grifols S.A. Stock (ES0171996087): IBEX 35 plasma specialist in focus after modest gain - Ad-hoc-news.de
GRIFOLS SA-ADR (GRFS) Stock Chart - ChartMill
Grifols Shares Edge Lower as Stock Tests Key Support ZoneVolatility Smirk - newsline.com
Grifols ADR (GRFS) Gains 1.47% as Shares Hold Above Key Support LevelSector Leader Stocks - newsline.com
Grifols S.A. stock (ES0171996087): Q1 2026 figures and rising short interest keep focus on Spanish p - AD HOC NEWS
Grifols S.A. stock (ES0171996087): Spain plasma specialist in focus after volatile trading week - AD HOC NEWS
GRFS Stock Price, Quote & Chart | GRIFOLS SA-ADR (NASDAQ:GRFS) - ChartMill
Grifols S.A. stock (ES0171996087): Debt reduction deal, Q1 update and what matters for US investors - AD HOC NEWS
Grifols S.A. stock (ES0171996087): plasma specialist regains momentum after earnings update - AD HOC NEWS
Grifols S.A. stock (ES0171996087): plasma specialist back in focus after debt and governance reset - AD HOC NEWS
Grifols SA stock (ES0171996087): AGM plans and Moody’s outlook shift put debt and governance back - AD HOC NEWS
Grifols SA stock (ES0171996087): shareholders eye 2026 AGM after Moody’s outlook boost - AD HOC NEWS
Brandes reports 24.31% stake in Grifols (NASDAQ: GRFS) in Schedule 13G/A - Stock Titan
Earnings call transcript: Grifols Q1 2026 sees mixed results with EPS beat - Investing.com
Grifols S.A. stock (ES0171996087): Leading player in plasma-derived medicines - AD HOC NEWS
Grifols S.A. stock (ES0171996087): Plasma therapy specialist faces pricing and regulatory headwinds - AD HOC NEWS
Earnings call transcript: Grifols Q1 2026 results show mixed signals, revenue miss - Investing.com
Grifols Q1 Earnings Call Highlights - Barchart
Mittleman Value Partners 2025 Year-End & Q1 2026 Investment Review - Seeking Alpha
Grifols (NASDAQ: GRFS) 2025 revenue rises as leverage and risk factors stay elevated - Stock Titan
CapEx per share of Grifols, S.A. Sponsored ADR Class B – LSX:A1J1E2 - TradingView
6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16] - Moomoo
Grifols S.A. stock (ES0171996087): Why does its plasma therapy model matter more for U.S. investors - AD HOC NEWS
Grifols, S.A. (GRFS) stock price, news, quote and history - Yahoo Finance UK
Grifols S.A. Stock: Navigating Debt Reduction Through US Biopharma IPO Plans Amid Market Pressures - AD HOC NEWS
Grifols S.A. stock surges as board approves potential US IPO for biopharma unit, unlocking value in - AD HOC NEWS
The Great Resurgence: A Deep Dive into Grifols S.A. (GRFS) in 2026 - FinancialContent
Grifols SA stock surges as board greenlights potential US IPO of plasma unit to slash debt and fuel - AD HOC NEWS
0.48%
0.05%
자본화:
|
볼륨(24시간):